998TiPPamiparib, a novel PARP 1/2 inhibitor, monotherapy for gBRCAm patients with recurrent ovarian, fallopian, and primary peritoneal cancer: An open-label, multicenter, phase II trial in China. (23rd October 2018) - Wu, X; Wang, J; Zhou, Q; Gu, T; Zhang, K; Liang, J; Mu, S; Ge, R; Yang, H; Huang, V; Brachmann, R; Wang, L; et al.